Aptevo Therapeutics completes 1-for-44 reverse stock split effective March 5, 2024

Aptevo Therapeutics Inc.

Stockholders approved reverse split at Special Meeting on February 5, 2024; board set ratio on February 27.
Certificate of Amendment filed with Delaware on March 4; effective at 5:01 p.m. ET on March 5.
Every 44 outstanding shares combined into 1 share; no fractional shares issued.
Split-adjusted trading on Nasdaq begins March 6; new CUSIP number 03835L 306.
Proportionate adjustments made to stock options, RSUs, warrants, and equity plan reserves.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aptevo Therapeutics Inc.: Amended certificate of incorporation to effect a 1-for-44 reverse stock split (effective 2024-03-05).

Change: charter amendment
Effective: 2024-03-05

Exact text from the filing

On March 4, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-44 reverse stock split of the Company’s outstanding common stock. The Amendment was effective at 5:01 p.m. Eastern Time on March 5, 2024 (the “Effective Time”).

View on SEC.gov

Browse all governance changes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-026223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.